- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
International Journal of Genomics
Volume 2013 (2013), Article ID 480534, 10 pages
Integrated Analysis of Long Noncoding RNA and Coding RNA Expression in Esophageal Squamous Cell Carcinoma
1Clinical Research Center, People’s Hospital of Zhengzhou, 33 Yellow River Road, Zhengzhou, Henan 45003, China
2Department of Pathology and Experimental Medicine, University of Calgary, Calgary, AB, Canada T2N 4N1
3Science and Education Department, Health Bureau of Zhengzhou, China
4Departments of Medical Genetics and Biological Sciences, University of Calgary, Calgary, AB, Canada T2N 4N1
Received 28 May 2013; Accepted 26 August 2013
Academic Editor: Soraya E. Gutierrez
Copyright © 2013 Wei Cao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Tumorigenesis is a complex dynamic biological process that includes multiple steps of genetic and epigenetic alterations, aberrant expression of noncoding RNA, and changes in the expression profiles of coding genes. We call the collection of those perturbations in genome space the “cancer initiatome.” Long noncoding RNAs (lncRNAs) are pervasively transcribed in the genome and they have key regulatory functions in chromatin remodeling and gene expression. Spatiotemporal variation in the expression of lncRNAs has been observed in development and disease states, including cancer. A few dysregulated lncRNAs have been studied in cancers, but the role of lncRNAs in the cancer initiatome remains largely unknown, especially in esophageal squamous cell carcinoma (ESCC). We conducted a genome-wide screen of the expression of lncRNAs and coding RNAs from ESCC and matched adjacent nonneoplastic normal tissues. We identified differentially expressed lncRNAs and coding RNAs in ESCC relative to their matched normal tissue counterparts and validated the result using polymerase chain reaction analysis. Furthermore, we identified differentially expressed lncRNAs that are co-located and co-expressed with differentially expressed coding RNAs in ESCC and the results point to a potential interaction between lncRNAs and neighboring coding genes that affect ether lipid metabolism, and the interaction may contribute to the development of ESCC. These data provide compelling evidence for a potential novel genomic biomarker of esophageal squamous cell cancer.
Esophageal squamous cell carcinoma (ESCC) is one of the most common types of cancer, and it ranks among the main causes of cancer deaths worldwide . There are marked regional variation and exceptionally high incidence in certain areas of China. Despite advances in multidisciplinary treatment of ESCC, 5-year survival rate remains poor. The initiatome  of ESCC is a complex dynamic biological process in genome space, and it may include multiple steps of genetic and epigenetic alterations , aberrations in expression of noncoding RNA (e.g., microRNAs) , and changes in the expression profile of coding genes [5, 6]. In past decades, expression profiling of coding genes has defined important signaling pathways involved in tumorigenesis. The latest knowledge of actively transcribed long noncoding RNAs (lncRNAs) from high-throughput sequencing is revealing an even greater complexity about cancer genome regulatory networks.
LncRNAs are endogenous cellular RNA transcripts, ranging from 200 to 100,000 nucleotides in length, and they lack an open reading frame of significant length (less than 100 amino acids) . LncRNAs are generally expressed at a lower level than protein-coding genes, and they display more tissue-specific and cell-specific expression patterns [8, 9]. LncRNAs were previously believed to be transcriptional noise, but now they have critical roles in development and differentiation as well as in the proliferation and progress of disease, including cancer . Mechanisms of action of transcribed lncRNAs are described as modifying chromatin architecture and regulating gene expression in a cis or trans manner. For example, H19 lncRNA cis-regulates IGF2 gene expression at the same genomic locus, and HOTAIR lncRNA is transcribed on Chr 12, and it transregulates HoxD gene on Chr 2. Additionally, lncRNAs have also been reported to coordinate the regulation of neighboring coding genes through a “locus control” process , which mediates the localization of genes within nuclear regions to favor their transcription through the formation of domains of histone modification and intra- or interchromosomal loops . Dysregulated lncRNAs have been identified with different screening methodologies in various types of cancer. For example, the cancer-related lncRNA, metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1), was identified by subtractive hybridization during screening for early non-small cell lung cancer with metastasis . Overexpression of MALAT-1 is highly predictive of poor prognosis and shortened survival time in early stage lung cancer. Overexpression of HOTAIR lncRNA was found in several solid tumors [14–17] in association with cancer metastasis, and increased HOTAIR expression in breast cancer is transcriptionally induced by estradiol . Prostate cancer associated lncRNA, PCGEM1 , and PCAT-1  appear to be prostate-specific regulators of cell apoptosis and proliferation. Recently, AFAP1-AS1 lncRNA was reported to be overexpressed in esophageal adenocarcinoma .
The handful of dysregulated lncRNAs in different cancers suggests that lncRNAs are an enigmatic component of the whole transcriptome, which may participate in tumorigenesis, invasion, and metastasis. Efforts are being made to explore the “lncRNAome” of various cancers with advanced high-throughput RNA sequencing technologies [8, 9], and dynamic changes in lncRNA expression have been observed in cancer cells during different stages of cancer development and during treatment . However, our understanding of the role of lncRNAs in cancer biology is still in an early stage, and a clearly defined, predictive set of biological functions for lncRNAs is lacking in cancer biology. Therefore, thorough searches and analyses of the interactions between lncRNA and coding genes may help to infer their potential biological roles.
In order to understand the role of lncRNAs in ESCC, we report a pilot study of the profiles of differentially expressed lncRNAs and coding RNAs from tumor and adjacent normal tissue of individual patients with ESCC. We assessed the whole transcriptomic landscape for potential interactions between lncRNAs and coding-gene expression. In particular, we evaluated the coding genes that are co-located and co-expressed with the differentially expressed lncRNAs during the genesis of ESCC.
2. Results and Discussion
2.1. Transcriptomic Landscape of ESCC
Our genome-wide gene expression profiling of both lncRNAs and coding genes from ESCC and adjacent nonneoplastic tissue was conducted to detect possible associations of lncRNAs with ESCC. We first asked whether these transcripts of 7,419 noncoding and 27,958 coding RNAs could distinguish ESCC from normal tissues. Figure 1(a) shows that the four ESCC samples are clustered together in one group and clearly separated from the samples of normal tissue. Next, we examined the whole transcriptomic pattern (lncRNAs + coding RNAs) from each sample and the landscapes of the whole transcriptome (represented by heatmaps in Figure 1(a)) of normal tissues differ from those of ESCC that exhibit more heterogeneous alterations. The overall changes from a respective normal to cancer state were also seen separately as a difference in expression profile of either the lncRNA or the coding RNA. These observations suggest that a potential dynamic interaction between lncRNAs and coding RNAs may be reshaping the landscape of the whole transcriptome during ESCC development.
To gain a detailed understanding of the biological themes of all RNA transcripts, we further identified those transcripts that are significantly and differentially expressed (DE) in ESCC tissue compared to matched normal tissue, based on the criteria described in the methods. There are 410 DE-lncRNAs and 1219 DE-mRNAs that represent about 5% of the transcripts in the respective microarrays (Supplementary Tables S1 and S2 available online at http://dx.doi.org/10.1155/2013/480534). DE-lncRAs distinguish a cancer cell from its normal cell state with three times fewer transcripts than DE-mRNAs (Figures 1(b) and 1(c)), suggesting that the DE-lncRNA profile is more informative and, potentially, a more faithful indicator of a specific cell state.
Enrichment analysis of DE-mRNAs demonstrated that the respective genes are involved in cancer-related pathways (Figure 1(d)). Since expression profiling of coding-RNA has been intensively studied in esophageal cancer, we validated 10 genes whose expression level in other studies [23–25] is significantly changed () by at least 2-fold relative to normal tissues (Table 1).
2.2. Expression of lncRNAs in ESCC
LncRNAs are emerging as a novel class of noncoding RNAs that are pervasively transcribed in the genome, but there is limited functional knowledge about them. High-throughput screening of lncRNAs from ESCC has been poorly studied, except for a recent report of overexpressed lncRNA, AFAP1-AS1, in esophageal adenocarcinoma . In our study, a total of 7,419 intergenic lncRNAs and other transcripts of uncertain coding potential were examined, and we identified 410 DE-lncRNAs in ESCC relative to adjacent normal esophageal tissues. We named the anonymous lncRNAs ESCC Associated Long noncoding RNAs (ESCCAL, Supplementary Table S1). Expression of HOTAIR lncRNA is increased in various cancers [14–17, 26], and it is also significantly increased in our analysis of ESCC (Figure 2(a)). In addition, we confirmed another two upregulated lncRNAs that are differentially expressed in ESCC and that we have named ESCCAL-1, and ESCCAL-5. The increased and differential expression of HOTAIR, ESCCAL-1 and ESCCAL-5 in ESCC tissue relative to adjacent nonneoplastic tissue was independently assessed with PCR methods in matched-pair tissue samples from three additional ESCC patients and the results are consistent with the microarray analysis (Figure 2(b)). Interestingly, except for HOTAIR, other previously reported lncRNAs (i.e., MALAT-1, PCAT-1 and AFAP1-AS1) are not differentially expressed in our analysis of ESCC. Therefore, the DE-lncRNAs that we have identified may be a unique property of ESCC, and we are currently using a population-based analysis to characterize these DE-lncRNAs as potential genomic biomarkers and regulatory elements in the dynamic process leading to ESCC.
2.3. LncRNAs Co-located and Co-expressed with Coding Genes in ESCC
LncRNAs have been reported to coordinate the regulation of neighboring coding genes through a “locus control” process . We wondered whether such a “locus control” process could operate in ESCC development, and, therefore, we searched neighboring genes of the 410 DE-lncRNAs in the genome. The majority (98.8%) of the 410 DE-lncRNAs harbor neighboring coding genes whose genomic locations are within ~5 kb upstream and ~1 kb downstream of the lncRNA and may extend to 1000 kb in both directions (Figure 3(a)). Interrogation of 538 coding genes that are neighbors of these DE-lncRNAs (DE-lncRNAs co-located genes) revealed predicted functions in 9 common pathways such as the AP1 transcription factor network, integrin-linked kinase signaling, several signaling pathways in adherens junctions, and FOXO family signaling (Figure 3(b)).
We asked whether any DE-lncRNAs co-located genes are also differentially expressed in ESCC. Analysis of the DE-lncRNAs co-located genes with DE-mRNA data set identified 76 genomically co-located and differentially co-expressed genes (Figure 3(c) and Table 2). Strikingly, the co-located and co-expressed genes with DE-lncRNAs may be involved in ether lipid metabolism pathways by the participation of the LPCAT1 gene encoding lysophosphatidylcholine acyltransferase1 and the PLD1 gene encoding phospholipase D1 (Figure 3(c)). The lncRNA ESCCAL-337 (chr3:171506370-171528740) was downregulated in ESCC and located at 22,068 bp downstream of the PLD1 gene, whose expression was also decreased in ESCC. In contrast, the lncRNA ESCCAL-356 (chr5:1544500-1567142 reverse strand) was downregulated in ESCC and located at 21,250 bp upstream of LPCAT1, whose expression was upregulated in ESCC (Figure 3(c)). LPCAT1 modulates phospholipid composition by catalyzing lysophosphatidylcholine into phosphatidylcholine, and overexpression of LPCAT1 was reported to create favorable conditions for cancer cell proliferation [27, 28]. Therefore, at least two of the DE-lncRNAs have the potential to contribute to ESCC by a “locus control” process with neighboring coding genes.
In conclusion, we performed a genome-wide survey of the expression of lncRNAs and coding mRNAs from paired samples of primary neoplastic tissue and adjacent nonneoplastic normal tissue from four individuals. The overall transcriptomic landscape (both lncRNAs and mRNAs) is able to distinguish malignant from normal tissue in each person. We discovered a set of differentially expressed lncRNAs and their co-located and co-expressed coding mRNAs and demonstrated that lncRNAs may be involved in ether lipid metabolism in ESCC. Our study provides genomic support for a model of a “locus control” process in ESCC and a framework for further experimental study.
3. Materials and Methods
Written informed consent was obtained from patients before surgery, and the study protocol was approved by the Institutional Review Board for the use of human subjects at Zhengzhou Hospital. Primary tumors and adjacent nonneoplastic tissues were obtained from patients with ESCC who underwent surgical treatment at Linxian Hospital in May 2012. All tissues were frozen in liquid nitrogen immediately after surgical resection. None of the patients had prior chemotherapy or radiotherapy, nor did they have any other serious diseases. All ESCC tissues were histopathologically diagnosed by at least two independent senior pathologists.
3.2. Microarray Hybridization
Total RNAs were extracted using Trizol reagent, following manufacturer’s instructions (Invitrogen, Carlsbad, CA, USA). The quality of RNAs was measured with a 2100 Bioanalyzer (Agilent technology, USA). Input of 100 ng of total RNA was used to generate Cyanine-3 labeled cRNA, according to the Agilent One-Color Microarray-Based Gene Expression Analysis Low for Input Quick Amp Labeling kit (v6.0). Samples were hybridized on Agilent SurePrint G3 Human GE K Microarray (Design ID 028004). Arrays were scanned with the Agilent DNA Microarray Scanner at a 3 μm scan resolution, and data were processed with Agilent Feature Extraction 18.104.22.168. The microarray data discussed in this article have been deposited in National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) and are accessible through (GEO) Series accession number GSE45350 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE45350).
3.3. Validation by Polymerase Chain Reaction (PCR)
PCR analysis was performed on additional matched ESCC and adjacent nonneoplastic tissues for selected lncRNAs. The primer sequences for PCR are as follows: HOTAIR, forward 5′-GGTAGAAAAAGCAACCACGAAGC-3′ and reverse 5′-ACATAAACCTCTGTCTGTGAGTGCC-3′; ESSCAL-1 (chr8:76121095-76189420 reverse strand), forward 5′-CCAGACAGCAGCAAAGCAAT-3′ and reverse 5′-GGAAGCAGCAAATGTGTCCAT-3′; ESSCAL-5 (chr2:216585154-216585719 forward strand), forward 5′-TACCAACATTGTCCACCGGG-3′ and reverse 5′-GCTGATGACAGTCCCTTGCT-3′. GAPDH was used as a control, forward 5′-CCGGGAAACTGTGGCGTGATGG-3′ and reverse 5′-AGGTGGAGGAGTGGGTGTCGCTGTT-3′. The thermocycle conditions are as follows: initial denaturation at 95°C for 10 minutes, followed by 94°C for 45 seconds, 65°C for 30 seconds, and 72°C for 1 minute for 15 cycles. Then, the annealing temperature was reduced by 0.5°C/cycle for the next 14 cycles, and the amplification was finished with another 24 cycles with the annealing temperature at 58°C. Final extension was at 72°C for 10 minutes. The amplicons were resolved in 2% agarose gel.
3.4. Bioinformatic Analysis
Intensity data were exported to GeneSpring 12.0 (Agilent Technologies, Santa Clara, CA, USA) for quantile normalization and the analysis of differentially expressed long noncoding RNAs and coding RNAs. Paired -test analysis was used to obtain probe sets whose magnitude of change in expression of RNAs between ESCC tissue and adjacent normal esophageal tissue was either greater or less than 2.0 fold and value < 0.05 ( values were corrected for multiple testing using the method of Benjamini-Hochberg). The normalized data containing 42544 probes were further analyzed using the R program. All control probes were removed. We then defined the coding (“NM_,” “XM_”) and noncoding (“lincRNA,” “NR_,” and “XR_”) genes in the normalized data according to the definition of RefSeq accession format (http://www.ncbi.nlm.nih.gov/projects/RefSeq/key.html). Differentially expressed long noncoding RNAs (DE-lncRNAs) and coding RNAs (DE-mRNAs) were further identified. The landscapes of the whole transcriptome (lncRNAs + coding RNAs) or all lncRNAs or all coding RNAs were analyzed with gene expression dynamic inspector (GEDI).
3.5. Co-Location and Co-Expression Analysis between DE-lncRNAs and DE-mRNAs
Genomic coordinates of DE-lncRNAs were imported to GREAT software (http://bejerano.stanford.edu/great/public/html/index.php) for co-location analysis. Neighboring coding genes were then matched with DE-mRNAs to obtain a co-expression dataset. Three subgroups of genes (DE-lncRNA co-located genes, DE-mRNAs, and co-expressed genes) were used for gene expression network analysis using Cytoscape software (v2.8.3).
|AFAP1-AS1:||Actin filament-associated protein 1 antisense RNA|
|ESCC:||Esophageal squamous cell carcinoma|
|lncRNA:||Long noncoding RNA|
|MALAT-1:||Metastasis-associated lung adenocarcinoma transcript 1|
|HOTAIR:||HOX antisense intergenic RNA|
|PCAT-1:||Prostate cancer associated noncoding RNA transcript 1|
|PCR:||Polymerase chain reaction.|
Wei Cao and Wei Wu contributed equally to this project.
The National Natural Science Foundation of China (no. 81171992) and the Zhengzhou Science and Technology Programme (121PPTGG494-8) supported this work. The authors thank Anne Haegert at The Laboratory for Advanced Genome Analysis at the Vancouver Prostate Centre, Vancouver, Canada, for expert technical support. They also thank GenomeSky Inc, Canada, for providing computational consultation.
- J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008,” International Journal of Cancer, vol. 127, no. 12, pp. 2893–2917, 2010.
- W. Wu and J. A. Chan, “Understanding the role of long noncoding RNAs in the cancer genome,” in Next Generation Sequencing in Cancer Research-Decoding Cancer Genome, W. Wu and H. Choudhry, Eds., pp. 199–215, Springer, New York, NY, USA, 2013.
- J. J. Hao, T. Gong, Y. Zhang et al., “Characterization of gene rearrangements resulted from genomic structural aberrations in human esophageal squamous cell carcinoma KYSE150 cells,” Gene, vol. 513, no. 1, pp. 196–201, 2013.
- M. Kano, N. Seki, N. Kikkawa et al., “MiR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma,” International Journal of Cancer, vol. 127, no. 12, pp. 2804–2814, 2010.
- H. Su, N. Hu, H. H. Yang et al., “Global gene expression profiling and validation in esophageal squamous cell carcinoma and its association with clinical phenotypes,” Clinical Cancer Research, vol. 17, no. 9, pp. 2955–2966, 2011.
- D. M. Greenawalt, C. Duong, G. K. Smyth et al., “Gene expression profiling of esophageal cancer: comparative analysis of Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma,” International Journal of Cancer, vol. 120, no. 9, pp. 1914–1921, 2007.
- I. Dunham, A. Kundaje, S. F. Aldred et al., “An integrated encyclopedia of DNA elements in the human genome,” Nature, vol. 489, no. 7414, pp. 57–74, 2012.
- E. A. Gibb, C. J. Brown, and W. L. Lam, “The functional role of long non-coding RNA in human carcinomas,” Molecular Cancer, vol. 10, article 38, 2011.
- A. L. Brunner, A. H. Beck, B. Edris et al., “Transcriptional profiling of lncRNAs and novel transcribed regions across a diverse panel of archived human cancers,” Genome Biology, vol. 13, no. 8, article R75, 2012.
- M. Guttman and J. L. Rinn, “Modular regulatory principles of large non-coding RNAs,” Nature, vol. 482, no. 7385, pp. 339–346, 2012.
- K. C. Wang, Y. W. Yang, B. Liu et al., “A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression,” Nature, vol. 472, no. 7341, pp. 120–126, 2011.
- A. Dean, “On a chromosome far, far away: LCRs and gene expression,” Trends in Genetics, vol. 22, no. 1, pp. 38–45, 2006.
- P. Ji, S. Diederichs, W. Wang et al., “MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer,” Oncogene, vol. 22, no. 39, pp. 8031–8041, 2003.
- R. A. Gupta, N. Shah, K. C. Wang et al., “Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis,” Nature, vol. 464, no. 7291, pp. 1071–1076, 2010.
- R. Kogo, T. Shimamura, K. Mimori et al., “Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers,” Cancer Research, vol. 71, no. 20, pp. 6320–6326, 2011.
- K. Kim, I. Jutooru, G. Chadalapaka et al., “HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer,” Oncogene, vol. 32, pp. 1616–1625, 2013.
- D. Li, J. Feng, T. Wu et al., “Long intergenic noncoding RNA HOTAIR is overexpressed and regulates PTEN methylation in laryngeal squamous cell carcinoma,” The American Journal of Pathology, vol. 182, no. 1, pp. 64–70, 2013.
- A. Bhan, I. Hussain, K. I. Ansari, S. Kasiri, A. Bashyal, and S. S. Mandal, “Antisense transcript long noncoding RNA (lncRNA) HOTAIR is transcriptionally induced by estradiol,” Journal of Molecular Biology, vol. 425, no. 19, pp. 3707–3722, 2013.
- D. Cejka, D. Losert, and V. Wacheck, “Short interfering RNA (siRNA): tool or therapeutic?” Clinical Science, vol. 110, no. 1, pp. 47–58, 2006.
- J. R. Prensner and A. M. Chinnaiyan, “The emergence of lncRNAs in cancer biology,” Cancer Discovery, vol. 1, pp. 391–407, 2011.
- W. Wu, T. D. Bhagat, X. Yang et al., “Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett's esophagus and esophageal adenocarcinoma,” Gastroenterology, vol. 144, no. 5, pp. 956–966, 2013.
- E. Özgür, U. Mert, M. Isin, M. Okutan, N. Dalay, and U. Gezer, “Differential expression of long non-coding RNAs during genotoxic stress-induced apoptosis in HeLa and MCF-7 cells,” Clinical and Experimental Medicine, vol. 13, no. 2, pp. 119–126, 2013.
- J. D. Li, Q. C. Feng, and J. S. Li, “Differential gene expression profiling of oesophageal squamous cell carcinoma by dna microarray and bioinformatics analysis,” Journal of International Medical Research, vol. 38, no. 6, pp. 1904–1912, 2010.
- S. Ma, J. Y. Bao, P. S. Kwan et al., “Identification of PTK6, via RNA sequencing analysis, as a suppressor of esophageal squamous cell carcinoma,” Gastroenterology, vol. 143, pp. 675–686, 2012.
- M. Tong, K. W. Chan, J. Y. Bao et al., “Rab25 is a tumor suppressor gene with antiangiogenic and anti-invasive activities in esophageal squamous cell carcinoma,” Cancer Research, vol. 72, no. 22, pp. 6024–6035, 2012.
- Y. J. Geng, S. L. Xie, Q. Li, J. Ma, and G. Y. Wang, “Large intervening non-coding RNA HOTAIR is associated with hepatocellular carcinoma progression,” Journal of International Medical Research, vol. 39, no. 6, pp. 2119–2128, 2011.
- X. Zhou, T. J. Lawrence, Z. He, C. R. Pound, J. Mao, and S. A. Bigler, “The expression level of lysophosphatidylcholine acyltransferase 1 (LPCAT1) correlates to the progression of prostate cancer,” Experimental and Molecular Pathology, vol. 92, no. 1, pp. 105–110, 2012.
- Y. Morita, T. Sakaguchi, K. Ikegami et al., “Lysophosphatidylcholine acyltransferase 1 altered phospholipid composition and regulated hepatoma progression,” Journal of Hepatology, vol. 59, no. 2, pp. 292–299, 2013.